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ABSTRACT
Objectives Persistent infection with high-risk sexually
transmitted human papillomaviruses (HR-HPVs) can lead
to development of cervical and other cancers, while low-
risk types (low-risk HPV) may cause genital warts. We
explored the epidemiology of different HPV types in men
and women and their association with demographic and
behavioural variables.
Methods We analysed data collected for the British
National Survey of Sexual Attitudes and Lifestyles,
a cross-sectional survey undertaken in 1999e2001. Half
of all sexually experienced male and female respondents
aged 18e44 years were invited to provide a urine
sample. We tested 3123 stored urine samples using an
in-house Luminex-based HPV genotyping system.
Results HPV DNA was detected in 29.0% (95% CI
26.7% to 31.3%) of samples from women and 17.4%
(95% CI 15.1% to 19.8%) from men. Any of 13 HR-HPV
types was detected in 15.9% (95% CI 14.1% to 17.8%)
of women and 9.6% (95% CI 8.0% to 11.6%) of men.
HPV types 16/18 were found in 5.5% (95% CI 4.5% to
6.8%) of women and 3.0% (95% CI 2.1% to 4.3%) of
men; and types 6/11 in 4.7% (95% CI 1.8% to 5.9%)
of women and 2.2% (95% CI 1.5% to 3.1%) of men. In
multivariate analysis, HR-HPV was associated with new
partner numbers, in women with younger age, single
status and partner concurrency, and in men with number
of partners without using condom(s) and age at ﬁrst
intercourse.
Conclusions HPV DNA was detectable in urine of a high
proportion of the sexually active British population. In
both genders, HR-HPV was strongly associated with risky
sexual behaviour. The minority of HPV infections were of
vaccine types. It is important to monitor HPV prevalence
and type distribution following the introduction of
vaccination of girls.
INTRODUCTION
Persistent infection with certain types of sexually
transmitted human papillomavirus (HPV) can lead
to the development of cervical and other cancers,
while other types cause the majority of genital
warts. HPV types that infect the genital area are
categorised as ‘high-risk’ HPV (HR-HPV) if known
to cause cervical cancer or ‘low-risk’ HPV (LR-HPV)
if not, albeit an imperfect categorisation.
1 2 Infection
with HR-HPV types is necessary but not sufﬁcient
for development of cervical cancer. Thirteen types
are currently recognised by the WHO International
Agency for Research on Cancer as ‘high risk’.
3
HR-HPV is also implicated in the aetiology of some
other anogenital cancers and of some oropharyn-
geal cancers.
4 Types 16 and 18 are associated with
>70% of cervical cancers worldwide.
5 Infection
with HPV types 6 or 11 is associated with the
majority of cases of anogenital warts.
6
Genital infection is often asymptomatic and
undiagnosed. However, genital warts remain the
most commonly diagnosed viral sexually trans-
mitted infection in the UK, with around 91000
cases diagnosed in genitourinary medicine clinics in
2009, an increase of 30% since 2000.
7 Transmission
is driven by the infectivity of the organisms, sexual
behaviour and the effectiveness of control inter-
ventions. Once infected, it is estimated that 70% of
women clear infection within 3 years.
8 Surveillance
of genital warts, detection of abnormalities by
cervical screening and cancer registrations give
some measures of the impact of HPV infection
but do not show the population prevalence or
distribution of HPV types.
An HPV immunisation programme was intro-
duced in the UK in 2008 for 12e13-year-old girls,
with a catch-up programme to age 18.
9 10 The
programme, to protect against cervical cancer, uses
the bivalent vaccine protecting against types 16 and
18, but not types 6 and 11, which the quadrivalent
vaccine offers.
Nationally representative epidemiological studies
are needed to inform HPV immunisation policy and
cervical cancer screening strategies and efforts to
improve uptake. The frequency of HR-HPV types
not present in current vaccines is an important
baseline against which to monitor any indirect
effect of vaccination on non-vaccine types (eg, type
replacement or cross-protection). Here, we examine
the proportion of men and women with detectable
HPV infection in urine samples archived from a
national probability sample survey of sexual atti-
tudes and lifestyles (Natsal-2) undertaken prior to
the introduction of HPV vaccination in Britain
and the relationship between infection and
demographic and behavioural variables.
11
METHODS
The second National Survey of Sexual Attitudes
and Lifestyles (Natsal-2) is a stratiﬁed probability
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Epidemiologysample survey of the population aged 16e44 years, resident in
Britain. Eleven thousand one hundred and sixty-one people, of
whom 6399 were women, were interviewed between May 1999
and February 2001. Details of the methodology are published
elsewhere.
11 Brieﬂy, a sample of 40523 addresses was selected
from the small-user Postcode Address File for Britain with
a multistage probability cluster design, with oversampling in
Greater London. Interviewers visited all selected addresses. One
resident aged 16e44 years from every eligible household was
invited after random selection to participate. Natsal-2 achieved
a response rate of 65.4%. Interviewers conducted interviews in
respondents’ homes. A face-to-face interview included questions
on socio-demographics, health behaviours, and ﬁrst sexual
experience. Respondents who reported no sexual experience of
any kind in the face-to-face interview and those aged 16 and
17 years with some heterosexual experience but no heterosexual
intercourse or same-sex experience reported in screening
questions were not given the subsequent computer-assisted self-
interview. This included questions on the number and gender of
sexual partners and sexual practices.
Five thousand and twenty-six respondents at alternate
sampled addresses, aged 18e44 years, who reported at least one
partner with whom they had sexual intercourse, were invited to
provide a urine sample for initial testing for genital Chlamydia
trachomatis (chlamydia) as previously reported.
12 Three thousand
ﬁve hundred and sixty-nine (71%) agreed and gave signed
informed consent for chlamydia testing and storage for anony-
mous future testing, providing 10 ml of urine in a plastic sterile
container containing 1 mg of boric acid. The interviewer posted
the urine sample to a central laboratory. Following testing for
chlamydia, samples were stored at  808C.
Ethical approval
Natsal-2 obtained ethical approval from University College
Hospital, North Thames Multicentre, and all local research
ethics committees in Britain. Approval for HPV testing of the
stored urine samples was obtained from St Mary’s Research
Ethics Committee (Ref: 07/Q0403/9).
Laboratory methods
Three thousand four hundred and thirty-six urine samples
stored at  808C were available. Three thousand one hundred
and twenty-three samples were adequate for testing using an in-
house Luminex-based genotyping assay for detection of HPV
types 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66,
68, 70, 73 and 82.
13 Each 1 ml urine sample was subjected to
centrifugation (13000 rpm for 20 min) and the pellet suspended
in 300 ml phosphate buffered saline before samples were lysed
(40 ml Qiagen Protease and 265 ml Qiagen Buffer AL) and nucleic
acids extracted on the BioRobot Universal platform (Qiagen;
QIAamp DNA Blood BioRobot MDx kit, Qiagen Limited,
Crawley, West Sussex, UK). Ten microlitres of the 100 ml eluted
material was used for PCR ampliﬁcation. HPV DNA (10 ml) was
ampliﬁed using the in-house single-round multiplex PCR. The
assay incorporated a control PCR to assess specimen integrity
and resolved type-speciﬁc infections using a genotyping assay
based on the Bio-Plex (Luminex xMAP, Bio-Rad Laboratories,
Hemel Hempstead, Hertfordshire, UK) platform.
Statistical methods
We did all statistical analyses in Stata (V.10)
14 accounting for
stratiﬁcation, clustering and weighting of the sample. We used
weighted data to correct for unequal selection probabilities and
to match the age/sex population proﬁle.
11 We examined the
relationship between HPV detection and socio-demographic and
behavioural factors and used multivariate analyses to identify
the factors associated with HR-HPV types detection. We deﬁned
HR-HPVas types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and
68 according to WHO International Agency for Research on
Cancer deﬁnition.
3 We used stepwise logistic regression to model
factors identiﬁed as statistically signiﬁcant at p<0.10 in the
bivariate analyses. The statistical signiﬁcance threshold for
inclusion in the ﬁnal multivariate model was p<0.10. To account
for differential demographic and behavioural response patterns
in willingness to provide a urine sample, the data were given an
additional weight, calculated by the inverse of the model-
predicted probability of responding.
12
RESULTS
Table 1 shows the prevalence of detectable HPV DNA by type in
urine for men and women. Any HPV DNA was detected in
29.0% of samples from women and 17.4% from men. Any HR-
HPV was detected in 15.9% of women and 9.6% of men. The
detected prevalence of either HR-HPV type in current vaccines
(HPV types 16 and 18) was 5.5% in samples from women and
3.0% from men, with 4.1% of women and 2.6% of men having
these types only. 9.8% of women and 4.8% of men had one of
the quadrivalent vaccine types (6, 11, 16 and 18). 3.4% of
women and 2.6% of men had two or more HR-HPV types
detectable.
Table 1 HPV DNA positivity by type and gender
Women Men
% (95% CI) % (95% CI)
Denominator* 1525, 1851 1545, 1272
HPV type
Any HPV 29.0 (26.7 to 31.3) 17.4 (15.1 to 19.8)
Any high risky 15.9 (14.1 to 17.8) 9.6 (8.0 to 11.6)
2+ high-risk typesy 3.4 (2.6 to 6.6) 2.6 (1.3 to 4.9)
High-risk type(s) 16 and/or 18 5.5 (4.5 to 6.8) 3.0 (2.1 to 4.3)
High-risk type(s) 16 and/or 18 only 4.1 (3.1 to 5.2) 2.6 (1.8 to 3.9)
Low-risk type(s) 6 and/or 11 4.7 (3.8 to 5.9) 2.2 (1.5 to 3.1)
Types 6/11/16/18 9.8 (8.4 to 11.3) 4.8 (3.7 to 6.3)
LR HPV-6 3.1 (2.3 to 4.2) 1.1 (0.7 to 1.9)
LR HPV-11 2.4 (1.8 to 3.3) 1.2 (0.7 to 2.0)
HR HPV-16 4.2 (3.3 to 5.3) 2.3 (1.5 to 3.5)
HR HPV-18 1.4 (0.9 to 2.2) 0.7 (0.3 to 1.4)
LR HPV-26 0.9 (0.5 to 1.6) 0.3 (0.1 to 1.0)
HR HPV-31 0.6 (0.3 to 1.1) 0.3 (0.1 to 0.9)
HR HPV-33 0.9 (0.6 to 1.5) 0.4 (0.1 to 0.9)
HR HPV-35 1.0 (0.6 to 1.6) 1.0 (0.5 to 1.8)
HR HPV-39 1.0 (0.6 to 1.6) 0.7 (0.3 to 1.5)
HR HPV-45 0.7 (0.4 to 1.2) 0.8 (0.4 to 1.6)
HR HPV-51 1.9 (1.3 to 2.7) 1.5 (1.0 to 2.4)
HR HPV-52 2.3 (1.7 to 3.2) 1.1 (0.6 to 1.9)
LR HPV-53 2.0 (1.4 to 2.8) 0.8 (0.4 to 1.5)
HR HPV-56 1.4 (0.9 to 2.1) 0.9 (0.5 to 1.9)
HR HPV-58 1.7 (1.2 to 2.4) 0.6 (0.3 to 1.2)
HR HPV-59 1.0 (0.5 to 1.8) 0.2 (<0.01 to 0.6)
LR HPV-66 0.9 (0.5 to 1.5) 0.6 (0.3 to 1.2)
HR HPV-68 1.8 (1.2 to 2.7) 0.9 (0.5 to 1.7)
LR HPV-70 1.0 (0.6 to 1.6) 0.4 (0.1 to 0.9)
LR HPV-73 0.9 (0.6 to 1.5) 0.4 (0.2 to 1.0)
LR HPV-82 <0.01 (<0.01 to 0.3) <0.01 (<0.01 to 0.6)
*Weighted, unweighted denominator deﬁned as respondents in Natsal-2 providing a urine
sample.
yDeﬁned as HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68.
HR HPV, high-risk human papillomavirus; LR HP, low-risk human papillomavirus.
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EpidemiologyFurther analyses examine the factors associated with HR-HPV
types. In both women and men, prevalence of detectable
HR-HPV declined with age from over one-quarter of women
aged 18e24 years to less than a tenth of women aged
40e44 years (supplemental table, available online). HR-HPV
was least frequent among those who were married but was not
associated with either educational status or social class. Since
over 90% of the sample was of white ethnicity, sample sizes for
non-white groups were too small to permit robust analysis of
ethnic variations.
In bivariate analysis, prevalence of HR-HPV was strongly
associated with sexual behaviour in men and women (supple-
mental table, available online). Prevalence fell with rising age at
ﬁrst intercourse, more markedly for men than women. HR-HPV
was strongly associated with increasing numbers of lifetime
partners, and, in the last year, the total number and new part-
ners, partners without a condom and partner concurrency
(ie, where dates of sex overlapped between the most recent
partner and the second most recent partner and/or the second
most recent partner and the third most recent partner). As an
example, prevalence rose from 11.3% of women with no
new partner in the last year to 42.3% of those with two or more
new partners in the last year (unadjusted OR 5.77 (95% CI 3.72
to 8.94)). Reporting ever having a same-sex partner was associ-
ated with HR-HPV in women but not in men. Smoking and
alcohol consumption were signiﬁcantly associated with
HR-HPV risk in men and women, as was oral contraception use
in women. HR-HPV was less common in circumcised men, but
this was of borderline statistical signiﬁcance. Reporting previous
STI diagnosis/es was signiﬁcantly associated with HR-HPV in
men only. Positivity for chlamydia was signiﬁcantly associated
with HR-HPV, with prevalence of 28.3% (95% CI 13.6% to
49.9%) and 9.2% (95% CI 7.5% to 11.2%) in men with and
without chlamydia infection, respectively, detected in their
urine (unadjusted OR 3.91 (95% CI 1.50% to 10.14%)) and
39.5% (95% CI 24.4% to 56.9%) and 15.4% (95% CI 13.7% to
17.4%) in women with and without chlamydia infection,
respectively, (unadjusted OR 3.57 (95% CI 1.74 to 7.34)).
We undertook a stepwise regression analysis to identify the
demographic and behavioural factors most strongly associated
with HR-HPV. Table 2 shows that for women, in the ﬁnal model,
HR-HPV remained signiﬁcantly associated with younger age,
being unmarried, increasing numbers of new sexual partners in
the last year and concurrency between the most recent sexual
partners in the last year. For men (table 3), HR-HPV remained
signiﬁcantly associated with younger age at ﬁrst sex, increasing
numbers of sexual partners without a condom in the last year
and the number of new sexual partners in the last year.
We also examined the relationship between receptive oral sex
and HPV. Receptive oral sex in the last year was commonly
reported by women (cunnilingus) (77.9%, 95% CI 75.8% to
80.0%) and by men (fellatio) (79.0%, 95% CI 76.2% to 81.6%).
HR-HPV DNA positivity was higher in those reporting recep-
tive oral sex, in men only (supplemental table, available
online). This indicates considerable potential for HPV trans-
mission to oropharyngeal sites of partners. The prevalence of
reporting receptive oral sex did not vary by age group among
men but declined signiﬁcantly among women aged
35e44 years. Heterosexual anal sex in the last year was
reported by 12.7%, (95% CI 10.9% to 14.8%) of men and 11.7%,
Table 2 Results from a stepwise logistic regression* to identify the key socio-demographic
characteristics, sexual behaviours and health-related factorsy associated with high-risk human
papillomavirus DNA positivity: women
% (95% CI)
Crude OR
(95% CI)
Adjusted OR
(95% CI) Denominatorz
All 15.9 (14.1 to 17.8) ee1525, 1851
Age at interview, years p<0.0001 p¼0.045
30+ 11.3 (9.5 to 13.3) 1.00 1.00 915, 1146
<30 22.7 (19.4 to 26.4) 2.32 (1.78 to 3.02) 1.37 (1.01 to 1.85) 610, 705
Marital status p<0.0001 p<0.0001
Married 7.2 (5.6 to 9.2) 1.00 1.00 741, 769
Cohabiting 20.7 (15.9 to 26.4) 3.37 (2.21 to 5.15) 2.73 (1.78 to 4.18) 280, 295
Previous married 21.8 (16.3 to 28.6) 3.61 (2.26 to 5.77) 2.68 (1.69 to 4.25) 138, 245
Single, never married 27.5 (23.2 to 32.3) 4.91 (3.49 to 6.90) 3.00 (1.99 to 4.53) 366, 542
Number of new sexual
partners,x last year
p<0.0001 p¼0.0006
0 11.3 (9.6 to 13.2) 1.00 1.00 1174, 1363
1 29.1 (23.3 to 35.5) 3.22 (2.28 to 4.55) 1.55 (1.08 to 2.22) 200, 293
2+ 42.3 (32.6 to 52.7) 5.77 (3.72 to 8.94) 2.47 (1.53 to 3.99) 98, 138
Concurrency between
most recent sexual
partners,x { last year
p<0.0001 p¼0.032
No 13.9 (12.2 to 15.9) 1.00 1.00 1333, 1599
Yes 31.1 (23.6 to 39.7) 2.78 (1.86 to 4.16) 1.59 (1.04 to 2.44) 101, 144
*Variables signiﬁcant at p<0.10 in the bivariate analyses (supplemental table, available online) were considered in the stepwise
logistic regression where the signiﬁcance level for addition to the model is p<0.10. Note that the resulting model also applies when
the signiﬁcance level for addition is p<0.05. When the signiﬁcance level for addition is p<0.01, there are only two variables in the
model: marital status and the ‘number of new opposite/same-sex partners, last year’. No pairwise interactions were statistically
signiﬁcant.
yIn order to make the model more statistically efﬁcient, response categories were collapsed where there were no signiﬁcant
differences between categories.
zWeighted, unweighted denominator deﬁned as respondents in Natsal-2 providing a urine sample. Respondents with data missing for
1+ variable(s) were excluded from the multivariate analyses.
xOpposite and/or same sex sexual partner(s).
{Respondents were asked to report the months and years of ﬁrst and last sex with their most recent partners (at most three partners).
Where these dates overlapped between their most recent partner and their second most recent partner and/or their second most
recent partner and their third most recent partner, it is assumed that the partnerships were concurrent.
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Epidemiology(95% CI 10.2% to 13.4%) of women. Women (only) reporting
this behaviour were more likely to be detectable HR-HPV DNA
positive.
For completeness, we also carried out analysis of the rela-
tionship between HPV 16 and/or 18 and demographic and
behavioural variables (data not shown). Given the lower preva-
lence, we had less power than for the analysis of any HR type,
but this analysis was broadly consistent with that for all
HR-HPV types (supplemental table, available online).
Of those found to have HPV 6 and/or 11, the types
predominantly associated with genital warts, only 1.9% (95% CI
0.6% to 6.2%) of women and 4.8% (95% CI 0.7% to 27.7%) of
men reported that they had been informed by a doctor that they
had genital warts/HPV infection.
The median age at ﬁrst intercourse was 17 for both women
and men. In an analysis of the time since ﬁrst intercourse (ﬁgure
1A,B), infection appears to be acquired in a high proportion of
young women within a year of ﬁrst intercourse, with a greater
Table 3 Results from a stepwise logistic regression* to identify the key socio-demographic
characteristics, sexual behaviours and health-related factorsy associated with human papillomavirus DNA
positivity of high-risk types: men
% (95% CI)
Crude OR
(95% CI)
Adjusted OR
(95% CI) Denominatorz
All 9.6 (8.0 to 11.6) ee1545, 1272
Age at ﬁrst heterosexual
sex, years
p¼0.0001 p¼0.0199
18+ 5.6 (3.6 to 8.5) 1.00 1.00 489, 417
16 or 17 9.5 (6.8 to 13.0) 1.77 (0.98 to 3.23) 1.23 (0.70 to 2.14) 572, 461
<16 15.7 (11.9 to 20.4) 3.16 (1.86 to 5.36) 2.06 (1.19 to 3.56) 429, 345
Number of sexual
partnersx without
a condom, last year
p<0.0001 p¼0.0106
0 3.6 (1.8 to 7.0) 1.00 1.00 319, 301
1 9.1 (7.1 to 11.5) 2.68 (1.25 to 5.77) 2.34 (1.13 to 4.89) 1001, 752
2+ 24.1 (17.0 to 33.1) 8.59 (3.71 to 19.9) 3.59 (1.56 to 8.29) 187, 186
Number of new sexual
partners,x last year
p<0.0001 p¼0.0347
0 6.7 (5.0 to 8.9) 1.00 1.00 1029, 786
1 12.7 (8.4 to 18.8) 2.03 (1.14 to 3.61) 1.33 (0.73 to 2.43) 240, 219
2+ 22.6 (16.7 to 29.8) 4.07 (2.51 to 6.59) 2.35 (1.23 to 4.48) 216, 220
*Variables signiﬁcant at p<0.10 in the bivariate analyses (supplemental table, available online) were considered in the stepwise
logistic regression where the signiﬁcance level for addition to the model is p<0.10. Note that the resulting model also applies when
the signiﬁcance level for addition is p<0.05. When the signiﬁcance level for addition is p<0.01, the only variable remaining signiﬁcant
in the model is the ‘number of opposite/same-sex partners without a condom, last year’. No pairwise interactions were statistically
signiﬁcant.
yIn order to make the model more statistically efﬁcient, response categories were collapsed where there were no signiﬁcant
differences between categories.
zWeighted, unweighted denominator deﬁned as respondents in Natsal-2 providing a urine sample. Respondents with data missing for
1+ variable(s) were excluded from the multivariate analyses.
xOpposite and/or same sex sexual partner(s).
Figure 1 (A) Detection of any high-risk human papillomavirus (HPV) by years since ﬁrst sexual intercourse: Females denominator: Sexually
experienced respondents aged 18e44 years in Natsal-2, 3-point moving average. (B) Detection of any high-risk HPV by years since ﬁrst sexual
intercourse: Males denominator: Sexually experienced respondents aged 18e44 years in Natsal-2, 3-point moving average. This ﬁgure is produced in
colour in the online journaldplease visit the website to view the colour ﬁgure.
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Epidemiologylag among men. This may reﬂect gender differences in the age of
ﬁrst sexual partners, as women tend to have ﬁrst intercourse
with partners who are older and who are more likely to be
sexually experienced.
15 Alternatively, or additionally, this may
reﬂect increased biological susceptibility to HPV infection of the
immature transformation zone in young girls.
DISCUSSION
This is the ﬁrst population-based probability sample study of
the distribution of sexually transmissible HPV types in Britain
with detailed analysis of the relationship with demographic and
behavioural variables, and including men. We have shown that
sexually transmissible HPV is highly prevalent in the population
with HPV DNA detectable in 29% of urine samples from women
and 17% of samples from men. However, of those infected, less
than one-third had HPV 16/18.
The overall HPV prevalence is similar to that observed for
women by the National Health and Nutrition Examination
Survey (NHANES) study in the USA in 2003e2004, which used
self-taken vaginal swabs (27% in women aged 14e59 years).
However, prevalence of HPV 16 DNA was higher in Natsal-2
(4.2%) than in NHANES (1.5%), as was HPV 18, at 1.4% in
Natsal-2 and 0.8% in NHANES.
16 This may in part be explained
by the younger age of the Natsal-2 participants and the
exclusion of participants with no sexual experience.
In common with other studies,
17 we detected HPV DNA less
frequently in samples from men than from women. This may
reﬂect genuine difference in prevalence. However, urine is
known to be an imperfect sample for detection of genital HPV
infection. In validation studies comparing HPV detection in
paired samples from urine and genital swabs from men and urine
and liquid-based cytology samples from women, we have shown
urine samples to have lower sensitivity, particularly in men,
although speciﬁcity approaches 100%,
13 consistent with the
work of others.
16 18 19 Taking account of the long period of
storage of samples in this survey and the lower sensitivity of
HPVassays in urine than in vaginal or urethral swabs, our results
are likely to be minimum estimates.
13
Men are key to the transmission of HPV to women, but
relatively little is known about HPV infection in men. The
sexual behaviour data in this population-based study allowed us
to demonstrate, despite the reduced sensitivity of the HPV
measure in men, which may lead to misclassiﬁcation, that
similar associations with behavioural characteristics are seen for
men as women. The prevalence in men is lower than that in the
recent paper by Giuliano et al,
20 but participants in that study
were drawn from a non-random sample in a number of countries
and testing was based on genital swabs so a direct comparison is
not possible here.
In NHANES, prevalence was highest in women aged
20e24 years and when the sexually inactive were excluded, and,
as in Natsal-2, prevalence then declined with increasing age.
16
Previous studies in England have shown that prevalence of HPV
is highest among the youngest women attending for cervical
screening.
21 These studies have not explored socio-demographic
and behavioural characteristics affecting these patterns.
Declining HPV DNA prevalence with age and with time from
ﬁrst intercourse is consistent with reduced partner change with
increasing age in Natsal-2,
11 clearance of infection over time,
with or without any naturally acquired immunity.
8
Socio-demographic and behavioural data allowed us to explore
the relationship between HPV and past and recent risk factors.
The strong relationship between HPV risk and sexual behaviour
was striking. In particular, we demonstrated the strong associa-
tion with recent acquisition of new partners in both sexes
consistent with HPVinfections being transient. While in bivariate
analysis, we are able to identify a range of health behavioural and
demographic variables associated with presence of HPV, in the
adjusted regression model, many of these behaviours no longer
remained signiﬁcant and are likely to have been confounders
rather than on the causal pathway. The association with chla-
mydia infection (detected in urine) is also likely to be the result of
confounding, as very similar risk factors have previously been
shown for chlamydia infection.
12 In our population, the minority
of men were circumcised, but there was some evidence in bivar-
iate analyses of a protective effect albeit of borderline statistical
signiﬁcance, while risk increased among those with multiple
partners and no condom use. Numerous studies have shown
associations between smoking, cervical cancer and HPV infec-
tion.
22 We have previously shown that those who have more
partners are likely to smoke and drink more alcohol.
23 24 In our
study, the association between smoking and HPV infection no
longer remained signiﬁcant in multivariate analysis suggesting
confounding of the association by sexual behaviour.
The observed increases in oropharyngeal squamous cell
carcinomas in recent years seem to be attributable to increasing
HR-HPV (HPV 16/18 in particular) and increasing practice of
orogenital sex.
25 In the ﬁrst National Survey of Sexual Attitudes
and Lifestyles undertaken in 1990e1991, we documented
a considerable increase in orogenital contact through the latter
half of the 20th century.
23 Given the high prevalence of
orogenital contact
11 and of HR-HPV in the Natsal-2 sample,
there is substantial potential for transmission of HR-HPV from
genital to oral sites of infection.
The high proportion of young women with detectable HPVand
the ﬁnding that many are infected within a year or two from ﬁrst
intercourse underscores the importance of delivering HPV vacci-
nation programmes before girls become sexually active. Our
analysis of HPV16/18 demonstrated similar risk factors to those for
all HR types and supports the existing policy to offer HPV vacci-
nation to all young women (younger than 18 years) in the UK and
may help to inform decisions about vaccination of some older
women. It is striking that despite the lower sensitivity of urine
Key messages
< Our data from a representative cross-sectional sample survey
of the British population allow for the ﬁrst time direct
comparison between men and women and the risk factors for
HPV acquisition.
< Sexually transmissible HPV is highly prevalent in the
population with HPV DNA detectable in 29% of urine
samples from women and 17% of samples from men.
However, of those infected, less than one-third had HPV
16 or 18.
< There is a very strong relationship in both men and women
between recent sexual partner change and HPV DNA and
rapid acquisition in women after ﬁrst intercourse. Condom use
has some protective effect even after taking account of
numbers of sexual partners.
< Our data provide evidence for the ongoing debate on the cost-
effectiveness of HPV vaccination in young men given the
increasing number of cancers, which are thought to be related
to HPV and the importance of continued sexual transmission
of HPV when only women are vaccinated.
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Epidemiologysamples in men for detecting HPV, it could be detected in a rela-
tively high proportion. This ﬁnding provides evidence for the
ongoing debate on the cost-effectiveness of vaccinating young men.
These estimates of sexually transmissible HPV frequency
prior to introducing vaccination in girls provide a baseline to
measure changes in vaccine- and non-vaccine-type HPV, in
vaccinated women and unvaccinated women and in men who
should beneﬁtf r o m‘herd immunity’ effects due to reduced
transmission of infection. HPV 16/18 vaccination has
been shown to confer some cross-protection against some
closely related non-vaccine HPV types, particularly HPV 31, 33
and 45.
26
HPV vaccination is an expensive public health intervention,
and it will be important to examine whether vaccination of
women reduces the prevalence of infection, in both genders. We
are currently undertaking on a third National Survey of Sexual
Attitudes and Lifestyles in which urine samples will be collected
and self-reported vaccine uptake measured. Fieldwork is sched-
uled to be completed in 2012 and will allow comparative
estimates between the two surveys a decade apart.
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